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June 2, 2009:2101–7ypertensive patients. Results of meta-analyses should be viewed
ith circumspection, especially when clinical practice might be
nfluenced (2). With one-fifth of the general population suscepti-
le to migraine (and other primary vascular headaches) and with
onvasodilating beta-blockers still regarded as first-line preventive
gents, the conclusions of this study (1) raise concern. The authors
dmittedly ignore the dose of atenolol (1), a critical variable that
imits this analysis. Besides, biologically, in no 2 patients can the
volution of atherosclerosis or its complications be strictly compa-
able. Statistics do permit such mathematical comparisons in
andomized controlled trials (RCTs), but they can extract a hidden
iological price (3).
First, contrary to the assertion that the “slower the heart rate,
he greater the benefit” (1), heart rates below 50 beats/min cannot
enerally be claimed to promote overall cardiovascular integrity.
econd, the negative inotropic action of beta-blockers has been
gnored in this study (1) as well as in the CAFE (Conduit Artery
unctional End Point) study (4). Any rise in central aortic
ressure/pulse pressure by nonvasodilating beta-blockers would be
ntrinsically countered by their negative inotropic action. A phar-
acologically reduced stroke volume would maximally affect cen-
ral conduit vessels to reduce central vessel wall stress. Not
urprisingly, atenolol reduces the elevated augmentation index in
ypertensive patients compared with that in normotensive subjects
5). Third, the investigators (1) did not stratify their results
ccording to age. An aging cohort is likely to have stiffer conduit
rteries that, in turn, would exacerbate any differential drug effects
n central aortic pressure (4). Fourth, the concept of dyssynchrony
r uncoupling between outgoing and reflected aortic waves conse-
uent to pharmacologically induced bradycardia (1) is purely
peculative.
Cardiovascular morbidity and mortality are too complex to be
esolved through multiple mathematics-based comparisons of
iverse pharmacologic agents, particularly when polytherapy with
everal drugs might be involved. Moreover, all vasodilators usually
orsen migraine headache; among antihypertensive agents, beta-
lockers, however, do not generally aggravate headache. Regardless
f age or race, hypertension is commonly associated with headache
hat has several features of migraine (6). Proscription of beta-
lockers for initial or primary management of hypertension will
ncrease the incidence of associated vascular headaches including
igraine and make their management more complex. Next,
eta-blockers hold center stage in management of predominantly
ystolic hypertension as well as the anxiety-related white coat
ypertension/effect. Weight gain and precipitation of diabetes
ellitus by beta-blockers is a relative risk unrelated to pancreatic
slet cell damage.
In essence, this study (1) and the accompanying editorial (7)
eek to convert a small-to-moderate statistical relative risk into an
bsolute biological risk with important practical implications.
CTs allow scientists to carry out credible research without having
o discern crucial clinical phenomena or diminishing the need for
he same (3). While using research tools such as RCTs or
eta-analysis involving RCTs, we must remain cognizant of the
ntrinsic biological limitations of mathematical data mining. To
eek or force a clinical/therapeutic consensus in the face of
iological uncertainty cannot be commended as the best scientific/
esearch practice. wVinod Kumar Gupta, MB, BS, MD
Gupta Medical Centre
ew Delhi 110 048
ndia
-mail: dr_vkgupta@yahoo.com
doi:10.1016/j.jacc.2008.11.064
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eta-Blocker–Induced
eart Rate Reduction
oo Simplistic to Explain the
eleterious Effects of Beta-Blockers
n their recently published article, Bangalore et al. (1) con-
luded, from a meta-regression analysis of 9 studies including a
otal of 34,096 patients taking beta-blockers as first-line therapy
nd 30,139 patients taking other antihypertensive agents, that
eta-blocker–associated reduction in heart rate increased the
isk of myocardial infarction, cardiovascular events, and death
or hypertensive patients. The authors suggested, as a mecha-
ism, that “pharmacologically induced bradycardia leads to
yssynchrony or uncoupling between outgoing and reflected
ave, thereby elevating central aortic pressure.” They referred
o the CAFE (Conduit Artery Functional End Point) study,
hich showed a higher central aortic systolic blood pressure
fter atenolol-based treatment than after amlodipine-based
reatment, and to the main ASCOT (Anglo-Scandinavian
ardiac Outcomes Trial) study showing a better predictive
alue for cardiovascular events of amlodipine-based treatment
han atenolol-based treatment. Although appealing, their con-
lusion that beta-blockers are deleterious through the reduction
n heart rate, thus increasing central pulse pressure, may be too
implistic and not supported by data.
Indeed, although the authors pointed out that resting heart rate
as an independent risk factor for cardiovascular morbidity and
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June 2, 2009:2101–7ortality for hypertensive patients, they did not analyze the
nfluence of baseline heart rate in their meta-analysis, a major
onfounding factor. We performed a similar meta-regression
nalysis in the same set of studies. We first checked that we
btained similar results concerning the influence of heart rate,
easured at the end of the trial in the beta-blocker group, on the
elative risk of myocardial infarction (Fig. 3 of Bangalore et al. [1]):
he equation derived from our analysis (y  2.593 – 0.0237x;
 0.0072) was very close to the equation (y  2.5794 – 0.0235x;
 0.0001) found by Bangalore et al. (1). We further analyzed the
nfluence of heart rate, measured at baseline in the beta-blocker
roup, on the relative risk of myocardial infarction, and found a
ignificant relationship (y  3.864 – 0.0380x; p  0.0001). The
ower the heart rate at baseline, the higher the relative risk of
yocardial infarction. Importantly, the slope of the later equation
baseline heart rate) was 1.6-fold higher (p  0.001) than that of
he former one (heart rate at the end of the trial). These results
uggest that heart rate at baseline (i.e., before any administration of
eta-blocker) is a better predictor of myocardial infarction than
eart rate at the end of the trial. The relative risk for myocardial
nfarction was higher than unity when baseline heart rate was lower
han 75.4 beats/min, and lower than unity when heart rate was
igher than this value.
Thus, heart rate at baseline may have acted as a confounding
actor in the analysis performed by Bangalore et al. (1). This
uggests that reduction in heart rate may not be the main
echanism through which beta-blockers devoid of vasodilating
roperties, particularly atenolol, exert deleterious effects on the
ardiovascular system, and demonstrate less effect than other
ntihypertensive agents for preventing cardiovascular events. In-
eed, in contrast to vasodilating agents like calcium-channel
lockers and renin-angiotensin system blockers, atenolol does not
educe total peripheral resistance and sympathetic drive, and fails
o induce the long-term remodeling of large and small arteries that
s required for structural improvement of arterial stiffness and
esistance and the reduction in wave reflection and central aortic
lood pressure.
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owering, Cardioprotection, and
ypertension
angalore et al. (1) have provided an intriguing observation that
ardiovascular (CV) events, including CV death, myocardial in-
arction, heart failure, stroke, and all-cause death, may be increased
n hypertensive patients placed on beta-blockers and that this may
e related to the degree of heart rate reduction. They have done
his by performing meta-regression analyses to demonstrate the
elationship between heart rate and cardiovascular outcomes.
However, the data in their graphs show that the regression lines
ross the line of unity. The 1 study that is consistently at or below
nity in their graphs is the IPPSH (International Prospective
rimary Prevention Study in Hypertension), which compared a
eta-blocker with placebo. Similarly, the only other placebo-
ontrolled trial analyzed, STOP (Swedish Trial in Old Patients
ith Hypertension) (2), shows a relative risk of about 0.9 in Figure
of Bangalore et al. (1). This suggests that beta-blockers are not
ncreasing CV events because there is no increase in events in
eta-blocker patients compared with placebo patients. The major
ifferences in outcome rates are in the studies comparing beta-
lockers with active controls.
These findings suggest that beta-blockers were less effective at
reventing CV events than other antihypertensive agents. The
echanism for this may be evident in Table 2 of Bangalore et al.
1), which shows that beta-blockers resulted in less blood pressure
eduction in 5 of 7 active control trials analyzed by the authors,
ith up to a 9.2-mm Hg difference in systolic blood pressure. This
uggests that beta-blockers were simply less effective antihyperten-
ive agents in general. Thus, an alternative interpretation of the
uthors’ findings is not that beta-blockers increase mortality, as has
een widely reported in the press, but that beta-blockers are simply
ess effective antihypertensive agents than diuretics or dihydropyr-
dine calcium-channel blockers. As a result, they are also less
ffective at preventing hypertension-related cardiovascular events
han other medications. The clinical message I would take from
his study is that we must remember that the primary goal of
ntihypertensive treatment is to lower blood pressure and not to
ower heart rate.
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